Larimar Therapeutics, Inc (LRMR)

Etorro trading 970x250
Larimar Therapeutics, Inc (LRMR) Logo

About Larimar Therapeutics, Inc

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company’s lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich’s ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania. Address: Three Bala Plaza East, Bala Cynwyd, PA, United States, 19004

Larimar Therapeutics, Inc News and around…

Latest news about Larimar Therapeutics, Inc (LRMR) common stock and company :

Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
19 May, 2022 Yahoo! Finance

BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase 1 clinical program evaluating CTI-1601 as a potential treatment for Friedreich's ataxia will be featured in two upcoming poster presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress, which is taking place May

Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
12 May, 2022 Yahoo! Finance

- CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Administration and is scheduled for early in the third quarter of 2022 - Cash at March 31, 2022 of $62.6 million provides projected cash runway into the third quarter of 2023 BALA CYNWYD, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first q

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Investor Alert: Investigation over Potential Wrongdoing
02 May, 2022 FinancialContent

San Diego, CA -- (SBWIRE) -- 05/02/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Larimar Therapeutics, Inc.

Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year
29 Apr, 2022 Yahoo! Finance

Some of the losses seen by insiders who purchased US$496k worth of Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) shares...

Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)
13 Apr, 2022 Yahoo! Finance

Larimar (LRMR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

IBBQ's Underlying Holdings Could Mean 48% Gain Potential
12 Apr, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Nasdaq Biotechnology ETF (IBBQ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $30.93 per unit.

Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
25 Mar, 2022 Yahoo! Finance

BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its full year 2021 operating and financial results. “The past year was highlighted by our first clinical data readouts, which demonstrated the potential of CTI-1601 to address the root cause of Friedreich’s ataxia by increasing frataxin levels in patients,” said Carole Ben-Maim

How The Pieces Add Up: BIB Targets $85
07 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $85.29 per unit.

Larimar Therapeutics, Inc. (NASDAQ:LRMR) Investor Notice: Investigation over Possible Violations of Securities Laws
02 Mar, 2022 FinancialContent

San Diego, CA -- (SBWIRE) -- 03/02/2022 -- Larimar Therapeutics, Inc is under investigation over potential securities laws violations in connection with certain financial statements.

12 Health Care Stocks Moving In Friday's Pre-Market Session
18 Feb, 2022 FinancialContent

Gainers Biofrontera (NASDAQ:BFRA) stock moved upwards by 11.8% to $3.49 during Friday's pre-market session. The ...

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Larimar Therapeutics, Inc. (LRMR) Investigation
17 Feb, 2022 FinancialContent

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Investors who purchased Larimar shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/lrmr.

12 Health Care Stocks Moving In Thursday's Pre-Market Session
17 Feb, 2022 FinancialContent

Gainers NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 12.3% to $3.0 during Thursday's pre-market ...

Larimar Therapeutics' stock plunges on FDA decision; could implement cost-cutting measures
16 Feb, 2022 Yahoo! Finance

The Food and Drug Administration dealt Larimar Therapeutics a setback when the agency decided to maintain its clinical hold on the Bala Cynwyd biotechnology company's effort to develop a treatment for a rare condition

55 Biggest Movers From Yesterday
16 Feb, 2022 FinancialContent

Check this out: Insiders Buy Around $112M Of 3 Stocks.Losers Larimar Therapeutics, Inc. (NASDAQ: LRMR) shares fell 52.1% to ...

Mid-Afternoon Market Update: Dow Jumps 400 Points; Marriott International Tops Q4 Views
15 Feb, 2022 FinancialContent

US stocks remained higher toward the end of trading session on Tuesday after Russia announced it would pull back some troops positioned ...

Mid-Day Market Update: Crude Oil Down 4%; US Producer Prices Rise 1% In January
15 Feb, 2022 FinancialContent

US stocks remained higher midway through trading on Tuesday after Russia announced it would pull back some troops positioned on the ...

Stocks That Hit 52-Week Lows On Tuesday
15 Feb, 2022 FinancialContent

Tuesday's session saw 95 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week ...

31 Stocks Moving In Tuesday's Mid-Day Session
15 Feb, 2022 FinancialContent

Gainers Resonant Inc. (NASDAQ: RESN) jumped 249% to $4.29 after Murata Electronics announced plans to buy the company at $4.50 per ...

Mid-Morning Market Update: Markets Open Higher On Easing Russia-Ukraine Tensions
15 Feb, 2022 FinancialContent

US stocks opened on a strong note this morning after Russia announced it would pull back some troops positioned on the Ukrainian ...

Futures Soar, Safe Havens Tumble After Russia Announces Some Troops Returning To Base
15 Feb, 2022 FinancialContent

With less than 24 hours to go until the Feb 16 CNN and CIA-leaked Putin "invasion day" - because if you are Russia you always leak to the US intel agencies when you are going to invade a sovereign nation.

Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2022
15 Feb, 2022 FinancialContent

Upgrades For Blue Bird Corp (NASDAQ:BLBD), Roth Capital upgraded the previous rating of Neutral to Buy. Blue Bird earned $0.07 in the ...

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
15 Feb, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer ...

Larimar Stock Plunges As FDA Asks For Additional Data To Resolve Clinical Hold On Friedreich's Ataxia Program
15 Feb, 2022 FinancialContent

Larimar Therapeutics Inc(NASDAQ: LRMR) hasreceived feedback from the FDAregarding the clinical hold on its CTI-1601 ...

22 Stocks Moving in Tuesday's Pre-Market Session
15 Feb, 2022 FinancialContent

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check this out: ...

Larimar Therapeutics Provides Update on CTI-1601 Clinical Program
14 Feb, 2022 Yahoo! Finance

BALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) regarding the clinical hold on Larimar’s CTI-1601 program. FDA stated it is maintaining its clinical hold at this time and that additional data is needed to resolve the clinical hold. Larimar is furt

41 Biggest Movers From Yesterday
27 Jan, 2022 FinancialContent

Gainers Ebang International Holdings Inc. (NASDAQ: EBON) shares gained 35.4% to settle at $1.09 on Wednesday as investors weighed ...

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?
19 Jan, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Larimar Therapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
22 Nov, 2021 Yahoo! Finance

BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage bio

In spite of Larimar Therapeutics, Inc.'s recent pullback, insiders still gained about US$85k after buying earlier this year.
20 Nov, 2021 Yahoo! Finance

Insiders who bought Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) in the last 12 months may probably not pay attention to...

Larimar Therapeutics to Participate in the Guggenheim Virtual Neuro/Immunology Conference
15 Nov, 2021 Yahoo! Finance

BALA CYNWYD, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in 1x1 investor meetings at the Guggenheim Virtual Neuro/Immunology Conference taking place November 15 – 16, 2021. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on

Larimar Therapeutics, Inc (LRMR) is a NASDAQ Common Stock listed in , ,

970x250